97
Views
1
CrossRef citations to date
0
Altmetric
Reviews

Chemoprophylaxis in colorectal cancer: current concepts and a practical algorithm for use

, , , &
Pages S57-S66 | Published online: 07 Apr 2010

Bibliography

  • Boyle P, Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann Oncol 2005;16:481-8
  • Sung JJ, Lau JY, Young GP, Asia Pacific consensus recommendations for colorectal cancer screening. Gut 2008;57:1166-76
  • Giardiello FM, Hamilton SR, Krush AJ, Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993;328:1313-6
  • Bae JM, Jung KW, Won YJ. Estimation of cancer deaths in Korea for the upcoming years. J Korean Med Sci 2002;17:611-5
  • Selby JV, Friedman GD, Quesenberry CP Jr, Weiss NS. A case-control study of screening sigmoidoscopy and mortality from colorectal cancer. N Engl J Med 1992;326:653-7
  • Arber N, Levin B. Chemoprevention of colorectal neoplasia: the potential for personalized medicine. Gastroenterology 2008;134:1224-37
  • Peipins LA, Sandler RS. Epidemiology of colorectal adenomas. Epidemiol Rev 1994;16:273-97
  • Neugut AI, Jacobson JS, De Vivo I. Epidemiology of colorectal adenomatous polyps. Cancer Epidemiol Biomarkers Prev 1993;2:159-76
  • Sung JJ, Chan FK, Leung WK, Screening for colorectal cancer in Chinese: comparison of fecal occult blood test, flexible sigmoidoscopy, and colonoscopy. Gastroenterology 2003;124:608-14
  • Choe JW, Chang HS, Yang SK, Screening colonoscopy in asymptomatic average-risk Koreans: analysis in relation to age and sex. J Gastroenterol Hepatol 2007;22:1003-8
  • US Preventive Services Task Force, Screening for colorectal cancer: recommendation and rationale. Am Fam Physician 2002;66:2287-90
  • Winawer S, Fletcher R, Rex D, Colorectal cancer screening and surveillance: clinical guidelines and rationale-update based on new evidence. Gastroenterology 2003;124:544-60
  • Tamakoshi K, Wakai K, Kojima M, A prospective study of reproductive and menstrual factors and colon cancer risk in Japanese women: findings from the JACC study. Cancer Sci 2004;95:602-7
  • Leung WK, Ho KY, Kim WH, Colorectal neoplasia in Asia: a multicenter colonoscopy survey in symptomatic patients. Gastrointest Endosc 2006;64:751-9
  • Byeon JS, Yang SK, Kim TI, Colorectal neoplasm in asymptomatic Asians: a prospective multinational multicenter colonoscopy survey. Gastrointest Endosc 2007;65:1015-22
  • Fuchs CS, Giovannucci EL, Colditz GA, A prospective study of family history and the risk of colorectal cancer. N Engl J Med 1994;331:1669-74
  • Johns LE, Houlston RS. A systematic review and meta-analysis of familial colorectal cancer risk. Am J Gastroenterol 2001;96:2992-3003
  • Dai Z, Xu YC, Niu L. Obesity and colorectal cancer risk: a meta-analysis of cohort studies. World J Gastroenterol 2007;13:4199-206
  • Tsong WH, Koh WP, Yuan JM, Cigarettes and alcohol in relation to colorectal cancer: the Singapore Chinese Health Study. Br J Cancer 2007;96:821-7
  • Seeff LC, Shapiro JA, Nadel MR. Are we doing enough to screen for colorectal cancer? Findings from the 1999 Behavioral Risk Factor Surveillance System. J Fam Pract 2002;51:761-6
  • Saito H. Colorectal cancer screening using immunochemical faecal occult blood testing in Japan. J Med Screen 2006;13 (Suppl 1):S6-7
  • Collins V, Meiser B, Gaff C, Screening and preventive behaviors one year after predictive genetic testing for hereditary nonpolyposis colorectal carcinoma. Cancer 2005;104:273-81
  • Sandler RS, Halabi S, Baron JA, A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003;348:883-90
  • Schatzkin A, Lanza E, Corle D, Lack of effect of a low-fat, high-fiber diet on the recurrence of colorectal adenomas. Polyp Prevention Trial Study Group. N Engl J Med 2000;342:1149-55
  • Greenberg ER, Baron JA, Tosteson TD, A clinical trial of antioxidant vitamins to prevent colorectal adenoma. Polyp Prevention Study Group. N Engl J Med 1994;331:141-7
  • Alberts DS, Martinez ME, Roe DJ, Lack of effect of a high-fiber cereal supplement on the recurrence of colorectal adenomas. Phoenix Colon Cancer Prevention Physicians' Network. N Engl J Med 2000;342:1156-62
  • Chlebowski RT, Wactawski-Wende J, Ritenbaugh C, Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med 2004;350:991-1004
  • Prentice RL, Langer R, Stefanick ML, Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the Women's Health Initiative clinical trial. Am J Epidemiol 2005;162:404-14
  • Flood A, Peters U, Chatterjee N, Calcium from diet and supplements is associated with reduced risk of colorectal cancer in a prospective cohort of women. Cancer Epidemiol Biomarkers Prev 2005;14:126-32
  • McCullough ML, Robertson AS, Rodriguez C, Calcium, vitamin D, dairy products, and risk of colorectal cancer in the Cancer Prevention Study II Nutrition Cohort (United States). Cancer Causes Control 2003;14:1-12
  • Terry P, Baron JA, Bergkvist L, Dietary calcium and vitamin D intake and risk of colorectal cancer: a prospective cohort study in women. Nutr Cancer 2002;43:39-46
  • Marcus PM, Newcomb PA. The association of calcium and vitamin D, and colon and rectal cancer in Wisconsin women. Int J Epidemiol 1998;27:788-93
  • Peters U, Chatterjee N, McGlynn KA, Calcium intake and colorectal adenoma in a US colorectal cancer early detection program. Am J Clin Nutr 2004;80:1358-65
  • Kesse E, Boutron-Ruault MC, Norat T, Dietary calcium, phosphorus, vitamin D, dairy products and the risk of colorectal adenoma and cancer among French women of the E3N-EPIC prospective study. Int J Cancer 2005;117:137-44
  • Sesink AL, Termont DS, Kleibeuker JH, Van der Meer R. Red meat and colon cancer: dietary haem-induced colonic cytotoxicity and epithelial hyperproliferation are inhibited by calcium. Carcinogenesis 2001;22:1653-9
  • Van der Meer R, Lapre JA, Govers MJ, Kleibeuker JH. Mechanisms of the intestinal effects of dietary fats and milk products on colon carcinogenesis. Cancer Lett 1997;114:75-83
  • Kallay E, Kifor O, Chattopadhyay N, Calcium-dependent c-myc proto-oncogene expression and proliferation of Caco-2 cells: a role for a luminal extracellular calcium-sensing receptor. Biochem Biophys Res Commun 1997;232:80-3
  • Chakrabarty S, Radjendirane V, Appelman H, Varani J. Extracellular calcium and calcium sensing receptor function in human colon carcinomas: promotion of E-cadherin expression and suppression of beta-catenin/TCF activation. Cancer Res 2003;63:67-71
  • Penman ID, Liang QL, Bode J, Dietary calcium supplementation increases apoptosis in the distal murine colonic epithelium. J Clin Pathol 2000;53:302-7
  • Palmer HG, Gonzalez-Sancho JM, Espada J, Vitamin D(3) promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of beta-catenin signaling. J Cell Biol 2001;154:369-87
  • Cross HS, Pavelka M, Slavik J, Peterlik M. Growth control of human colon cancer cells by vitamin D and calcium in vitro. J Natl Cancer Inst 1992;84:1355-7
  • Cross HS, Kallay E. Regulation of the colonic vitamin D system for prevention of tumor progression: an update. Future Oncol 2009;5:493-507
  • Wactawski-Wende J, Kotchen JM, Anderson GL, Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med 2006;354:684-96
  • Cho E, Smith-Warner SA, Spiegelman D, Dairy foods, calcium, and colorectal cancer: a pooled analysis of 10 cohort studies. J Natl Cancer Inst 2004;96:1015-22
  • Gorham ED, Garland CF, Garland FC, Vitamin D and prevention of colorectal cancer. J Steroid Biochem Mol Biol 2005;97:179-94
  • Mizoue T, Kimura Y, Toyomura K, Calcium, dairy foods, vitamin D, and colorectal cancer risk: the Fukuoka Colorectal Cancer Study. Cancer Epidemiol Biomarkers Prev 2008;17:2800-7
  • Ishihara J, Inoue M, Iwasaki M, Dietary calcium, vitamin D, and the risk of colorectal cancer. Am J Clin Nutr 2008;88:1576-83
  • Baron JA, Beach M, Mandel JS, Calcium supplements for the prevention of colorectal adenomas. Calcium Polyp Prevention Study Group. N Engl J Med 1999;340:101-7
  • Bergsma-Kadijk JA, van 't Veer P, Kampman E, Burema J. Calcium does not protect against colorectal neoplasia. Epidemiology 1996;7:590-7
  • Grau MV, Baron JA, Sandler RS, Vitamin D, calcium supplementation, and colorectal adenomas: results of a randomized trial. J Natl Cancer Inst 2003;95:1765-71
  • Allgayer H. Review article: mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease. Aliment Pharmacol Ther 2003;18 (Suppl 2):10-4
  • Gasche C, Goel A, Natarajan L, Boland CR. Mesalazine improves replication fidelity in cultured colorectal cells. Cancer Res 2005;65:3993-7
  • Velayos FS, Terdiman JP, Walsh JM. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol 2005;100:1345-53
  • van Staa TP, Card T, Logan RF, Leufkens HG. 5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study. Gut 2005;54:1573-8
  • Moody GA, Jayanthi V, Probert CS, Long-term therapy with sulphasalazine protects against colorectal cancer in ulcerative colitis: a retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire. Eur J Gastroenterol Hepatol 1996;8:1179-83
  • Eaden J, Abrams K, Ekbom A, Colorectal cancer prevention in ulcerative colitis: a case-control study. Aliment Pharmacol Ther 2000;14:145-53
  • Hawk ET, Levin B. Colorectal cancer prevention. J Clin Oncol 2005;23:378-91
  • Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995;83:493-501
  • Pai R, Soreghan B, Szabo IL, Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med 2002;8:289-93
  • Eberhart CE, Coffey RJ, Radhika A, Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994;107:1183-8
  • Piazza GA, Keeton AB, Tinsley HN, A novel sulindac derivative that does not inhibit cyclooxygenases but potently inhibits colon tumor cell growth and induces apoptosis with antitumor activity. Cancer Prev Res 2009;2:572-80
  • Rigau J, Pique JM, Rubio E, Effects of long-term sulindac therapy on colonic polyposis. Ann Intern Med 1991;115:952-4
  • Waddell WR, Loughry RW. Sulindac for polyposis of the colon. J Surg Oncol 1983;24:83-7
  • Winde G, Schmid KW, Schlegel W, Complete reversion and prevention of rectal adenomas in colectomized patients with familial adenomatous polyposis by rectal low-dose sulindac maintenance treatment. Advantages of a low-dose nonsteroidal anti-inflammatory drug regimen in reversing adenomas exceeding 33 months. Dis Colon Rectum 1995;38:813-30
  • Labayle D, Fischer D, Vielh P, Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 1991;101:635-9
  • Nugent KP, Farmer KC, Spigelman AD, Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br J Surg 1993;80:1618-9
  • Niv Y, Fraser GM. Adenocarcinoma in the rectal segment in familial polyposis coli is not prevented by sulindac therapy. Gastroenterology 1994;107:854-7
  • Baron JA, Cole BF, Sandler RS, A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003;348:891-9
  • Benamouzig R, Deyra J, Martin A, Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial. Gastroenterology 2003;125:328-36
  • Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999;340:1888-99
  • Cancer IAfRo. Non-steroidal anti-inflammatory drugs; 1997
  • Steinbach G, Lynch PM, Phillips RK, The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;342:1946-52
  • Zell JA, Pelot D, Chen WP, Risk of cardiovascular events in a randomized placebo-controlled, double-blind trial of difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas. Cancer Prev Res 2009;2:209-12
  • Silverstein FE, Faich G, Goldstein JL, Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000;284:1247-55
  • Arber N, Eagle CJ, Spicak J, Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006;355:885-95
  • Bresalier RS, Sandler RS, Quan H, Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092-102
  • Baron JA, Sandler RS, Bresalier RS, A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology 2006;131:1674-82
  • Bertagnolli MM, Eagle CJ, Zauber AG, Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006;355:873-84
  • Solomon SD, McMurray JJ, Pfeffer MA, Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352:1071-80
  • Rex DK, Cutler CS, Lemmel GT, Colonoscopic miss rates of adenomas determined by back-to-back colonoscopies. Gastroenterology 1997;112:24-8
  • Hixson LJ, Fennerty MB, Sampliner RE, Garewal HS. Prospective blinded trial of the colonoscopic miss-rate of large colorectal polyps. Gastrointest Endosc 1991;37:125-7
  • Myers RE, Balshem AM, Wolf TA, Adherence to continuous screening for colorectal neoplasia. Med Care 1993;31:508-19
  • Hardcastle JD, Chamberlain JO, Robinson MH, Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996;348:1472-7
  • Robinson MH, Marks CG, Farrands PA, Screening for colorectal cancer with an immunological faecal occult blood test: 2-year follow-up. Br J Surg 1996;83:500-1
  • Cole SR, Young GP, Byrne D, Participation in screening for colorectal cancer based on a faecal occult blood test is improved by endorsement by the primary care practitioner. J Med Screen 2002;9:147-52
  • Seeff LC, Nadel MR, Klabunde CN, Patterns and predictors of colorectal cancer test use in the adult U.S. population. Cancer 2004;100:2093-103
  • Zarychanski R, Chen Y, Bernstein CN, Hebert PC. Frequency of colorectal cancer screening and the impact of family physicians on screening behaviour. CMAJ 2007;177:593-7
  • Deutekom M, van Rijn AF, Dekker E, Uptake of faecal occult blood test colorectal cancer screening by different ethnic groups in the Netherlands. Eur J Public Health 2009;16:16
  • Bonithon-Kopp C, Kronborg O, Giacosa A, Calcium and fibre supplementation in prevention of colorectal adenoma recurrence: a randomised intervention trial. European Cancer Prevention Organisation Study Group. Lancet 2000;356:1300-6

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.